Outcomes and Prognostic Analysis of Surgical Resection for Oligometastasis from Hepatocellular Carcinoma

OSHITA KO

KOBAYASHI TSUYOSHI

TADOKORO TAKESHI

NAMBA YOSUKE

FUKUHARA SOTARO

MATSUBARA KEISO

TAKEI DAISUKE

HONMYO NARUHIKO

KURODA SHINTARO

KAWAOKA TOMOKAZU

AIKATA HIROSHI

OHDAN HIDEKI

Anticancer Research

Background/Aim: This study aimed to evaluate the outcomes of patients who underwent resection for oligometastasis from hepatocellular carcinoma (HCC) and identify the prognostic factors associated with poor survival. Patients and Methods: Patients who underwent resection for oligometastasis from HCC between January 2000 and April 2021 were retrospectively investigated. Oligometastasis was defined as 1-5 single organ metastases that were detected preoperatively in this study. Clinical characteristics and treatment outcomes were analyzed, and independent risk factors for poor prognosis were identified using cox proportional hazards model. Results: A total of 33 patients were included in this study. Eleven oligometastases were located in the intraabdominal lymph node, 8 in the adrenal gland, 5 in the lung, 4 in the peritoneum, 3 in the pleura, and 1 each in the supraclavicular lymph node and abdominal wall. No re-operation or operative death occurred in this study. The median OS was 44.6 months (range=5.1-150.6 months), and the median survival after primary HCC diagnosis was 116.5 months (range=7.1-253.6 months). The median cumulative incidence of recurrent HCC was 7.2 months (range=0.3-94.7 months). The multivariate analysis showed that an alpha-fetoprotein level ≥20 ng/ml and multiple primary HCC tumors were independent poor prognostic factors. Conclusion: Clinical characteristics and treatment outcomes of patients who underwent resection for oligometastasis from HCC were demonstrated. A high alpha-fetoprotein level and multiple primary HCC tumors were independent poor prognostic factors. Surgical resection can be one of the treatment options for oligometastasis from HCC.

Hepatocellular carcinoma

oligometastasis

surgical resection

eng

International Institute of Anticancer Research

Copyright © 2023 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

This is not the published version. Please cite only the published version.

この論文は出版社版ではありません。引用の際には出版社版をご確認、ご利用ください。

[DOI] https://doi.org/10.21873/anticanres.16720 isVersionOf

日本医療研究開発機構

Japan Agency for Medical Research and Development (AMED)

[Crossref Funder] https://doi.org/10.13039/100009619

分化制御NK細胞を用いた免疫療法による新規肝炎/肝癌治療の開発研究

分化制御NK細胞を用いた免疫療法による新規肝炎/肝癌治療の開発研究

JP22fk0210108